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Abstract
Background: Pseudomonas aeruginosa is an important cause of nosocomial infection and may lead
to septicemia and death. We evaluated the immunogenicity of semi-purified exotoxin A from the
bacterium in a mouse burn model.
Methods: The toxoid was prepared from exotoxin A taken from toxigenic strains of P. aeruginosa
(PA 103). 50 mice were immunized with the toxoid, burned with hot metal and infected with 1 ×
108 CFU of toxigenic strains of P. aeruginosa (experimental group); 25 non-immunized mice were
also burned and infected (control group). The mortality rate and presence of any exotoxin and P.
aeruginosa in the sera, liver and spleen were determined.
Results: In the experimental group, 2 mice died before the burns were administered and were
excluded from the study. The remainder (48 mice) were challenged with a lethal dose of P.
aeruginosa and followed for 70 days. 3 of these mice died. Neither P. aeruginosa nor exotoxin A was
not detected in the liver, spleen or sera of the surviving mice. The protective efficacy of toxoid
vaccination was therefore 93.8%. In the control group, all mice died from bacteremia and
septicemia, most (80%) within 6 days, and P. aeruginosa and exotoxin A were isolated from sera,
spleen and liver.
Conclusion:  Active immunization of mice using a semi-purified exotoxin A derived from P.
aeruginosa was 93.8% effective at protecting mice from subsequent P. aeruginosa infections in a
mouse burn model.
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Background
Pseudomonas aeruginosa is an opportunistic, non-fermenta-
tive, gram-negative rod which is an important cause of
nosocomial infection leading to septicemia and death [1].
The mortality rate is higher than bacteremias caused by
other gram-negative opportunistic pathogens. One of the
most important features of the bacterium is its resistance
to various antibacterial agents [2,3], and even newly
developed antibiotics have failed to reduce the mortality
rate associated with this organism [4].
There is increasing interest in bacterial virulence factors as
a basis for effective vaccines and immunotherapies. Sev-
eral extracellular products from P. aeruginosa such as exo-
toxin A, exoenzyme S, phospholipase and hemolysins
have been studies as potential virulence factors [5]. The
role of exotoxin A in the mortality of experimentally-
infected animals has been demonstrated [6] and the LD50
of the exotoxin reported to be 60–80 ng/mouse [7]. Fol-
lowing a single injection of 80 ng of exotoxin A, necrosis,
and cellular swelling were detected in liver within 48 h
[7]. Hemorrhage in the lungs and necrosis in the kidneys
were also reported [7,8]. In eukaryotic cells, when exo-
toxin A turns into an activated enzyme, transfer of an ade-
nosine diphosphate ribose moiety from NAD led to
inactivation of elongation factor 2 and inhibition of pro-
tein synthesis [7]. Furthermore, the pre-existence of a high
titer of anti-exotoxin A antibody reportedly increased the
survival rate in patients with P. aeruginosa bacteremia [9].
This study was performed to determine the immunogenic-
ity of a toxoid produced from exotoxin A of P. aeruginosa
in a mouse burn model.
Methods
Preparation of exotoxin A
A toxigenic strain of P. aeruginosa (PA 103) was used for
exotoxin A preparation. Exotoxin A was partially purified
according to the method described by Pollack et al. [10]
and Homma et al. [11]. P. aeruginosa was inoculated into
tryptic soy agar and incubated at 37°C for 24 h in ambient
conditions. The growth product of the slant cultures was
inoculated into 500 mL of Muller-Hinton broth and incu-
bated at 37°C for another 24 h in ambient conditions.
The bacterial suspension was centrifuged for 30 min at
2000 g and the supernatant containing exotoxin A was
sterilized by the Millipore filtration method (0.45 μm)
and concentrated 10× by polyethylene glycol (PEG) in a
dialysis bag (30 mm diameter, Biogen, Mashhad, Iran).
200 mL of the concentrated supernatant was mixed with
200 mL of diethyl amino ethyl cellulose and stirred at
4°C. Exotoxin A was precipitated by the addition of 0.25
M of NaCl and 70% saturated ammonium sulfate. The
precipitate was dissolved in 0.1 M of Tris hydrochloride
buffer containing 0.5 M of NaCl and 0.02% of NaN3 (pH
8 at 4°C) and then applied into a column packed with
Sephadex G75. The various fractions were collected and
concentrated in dialysis bags (10 mm diameter, Biogen,
Mashhad, Iran). Concentrated semi-purified exotoxin A
was examined for presence of exotoxin A using the coun-
ter immunoelectrophoresis (CIEP) method. The protein
content of exotoxin A was adjusted to 50 μg/mL by a spec-
trophotometer and used to immunize the mice.
Animal selection
75 white out-bred mice were provided from the Labora-
tory Animal Research Center of the Shiraz University of
Medical Sciences, housed in an ambient temperature of
21 ± 2°C and relative humidity of 65–70%, and given a
balanced diet with free access to food and water. Animal
selection, all experiments, subsequent care and the sacri-
fice procedure were all performed according to the guide-
lines and under the supervision of the Animal Care
Committee of the Iran Veterinary Organization. The pro-
tocol for anesthesia, burn induction, post-burn care and
sacrifice were identical for all animals. The animals were
sacrificed under deep ether general anesthesia. All experi-
ments were carried out under aseptic conditions. The
study was approved by the Ethics Committee of the Shiraz
University of Medical Sciences.
Determination of LD50
To determine the LD50 of the exotoxin, 50 additional
mice were divided into 10 equal groups. A series of dilu-
tions, up to ten-fold, of 50 μg/mL of semi-purified exo-
toxin A were prepared in PBS (pH 7.2). Each of the 10
groups was assigned to one of the 10 dilutions, and 1 mL
of solution was injected intraperitoneally in each animal.
Therefore, the mice received between 0.0005 and 5 μg of
exotoxin A. The mice were followed for 30 days. The LD50
was determined according to the Reed and Muench
method [13] and calculated to be 0.5 μg.
Preparation of toxoid
To prepare the toxoid, 5 mL of semi-purified exotoxin A
was mixed with 10 mL of PBS, pH 7.2, containing 0.01 M
sodium phosphate, 0.15 M sodium chloride and 4% for-
maldehyde, and incubated at 37°C for 4 days before
being dialyzed against phosphate buffer for 48 h. The
attenuated toxin was sterilized by Millipore filtration
(0.45 μm).
Mice immunization with toxoid
50 mice were assigned to the experimental group. 2 mice
died before the burns were administered and were not
enrolled in the study. The remaining 48 mice were immu-
nized with the toxoid. Each mouse received weekly subcu-
taneous injections for 6 weeks. Each injection contained
100 μg of semi-purified toxoid in 2 mL of PBS. 1 week
after the last injection, the animals were bled from the eyeBMC Microbiology 2009, 9:23 http://www.biomedcentral.com/1471-2180/9/23
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and the samples checked for the presence of antitoxin
using CIEP. To determine more precisely the ranges of
immunity in the vaccinated mice, the titer of anti-exo-
toxin A was measured by enzyme-linked immunosorbent
assay (ELISA) as previously described [14].
Rabbits hyperimmunization with toxoid
A group of 4 rabbits were immunized with the toxoid.
Each rabbit received weekly subcutaneous injections for 6
weeks. Each injection contained 200 μg of semi-purified
toxoid in 4 mL of PBS. 1 week after the last injection, the
animals were bled from the ear. Sera were pooled and the
presence of antitoxin against P. aeruginosa confirmed by
CIEP. The sera were used as an antitoxin when necessary,
to evaluate the presence of the toxin in the sera of the
experimental and control mice.
Counterimmunoelectrophoresis
CIEP was carried out for qualitative detection of toxin and
antitoxin in the sera of the immunized mice [12]. This
technique was applied on 13 × 18 cm glass slides which
were covered by 1% melted agarose in acetate buffer (pH
7.6). 2 rows of wells with a diameter of 6 × 6 mm were
punched in each glass slide and 0.4 mL of semi-purified
exotoxin A or serum containing the exotoxin A (antigen)
and 0.4 mL of immunized mice or rabbit serum (anti-
body) were placed in the anodal and cathodal wells,
respectively. The slide was subjected to electrophoresis
using an acetate buffer (pH 7.6 at 40 mA for 30 min). Pro-
duction of a precipitation line between the two wells indi-
cated the presence of antitoxin or toxin A in the sera. The
Amidoblack staining method was used to reveal the pre-
cipitation lines more clearly.
Determining the efficacy of the candidate vaccine
73 mice (48 immunized = experimental group, 25 non-
immunized = control group) were anesthetized and burns
(grade 3) were induced on the thigh using a 1 × 2 cm piece
of hot metal, producing a burn of up to 10% of the total
body surface and extending to all layers of skin but not
involving the muscular tissue. After 24 h, 108 colony form-
ing units (CFU) of toxigenic strains of P. aeruginosa (PA
103) were inoculated subcutaneously into the burned
area.
Both groups were supervised in their cages for 70 days.
Samples were obtained from the infected areas using ster-
ile swabs and saline and checked for the presence of P. aer-
uginosa at different time intervals. Blood samples and the
tissue samples of spleens and livers of dead mice were also
examined for presence of P. aeruginosa. The presence of P.
aeruginosa was determined as CFU/mL of the blood sam-
ples. The quantity of P. aeruginosa in the spleens and livers
was measured as the number of CFU per 1 g of homoge-
nized tissue. The survival rate in both groups was com-
pared. The efficacy of vaccine was calculated as the
percentage survival during the 70-day observation period
following inoculation with toxogenic P. aeruginosa (PA
103).
Confirmation of infection
Using sterile swabs and saline, samples were obtained
from the infected burns. The swabs were cultured on
blood and Muller-Hinton agar plates and incubated at
37°C under ambient conditions for 24 h. P. aeruginosa
was diagnosed by colony morphology, a zone of hemoly-
sis and oxidase, methyl red, Voges Proskauer, citrate and
TSI tests [15].
Results and discussion
Mice immunized with a semi-purified exotoxin A from P.
aeruginosa (n = 48) and non-immunized mice (n = 25)
received full-thickness burns to the skin of the thigh and
were then challenged with 108 CFU of P. aeruginosa (a
lethal dose). They were followed for 70 days. Antitoxin
and exotoxin A were detected in the sera of the experimen-
tal group by CIEP. The antibody titer ranged from 1:16 to
1:512 in the immunized mice using ELISA (Table 1).
During the follow-up period, 3 mice (6.3%) in the exper-
imental group died. All non-immunized mice developed
septicemia and died within 3 weeks of inoculation with P.
aeruginosa. In serial wound swabs (diluted in 1 ml of dis-
tilled water) from the immunized mice, 1.5 × 108 CFU/mL
of P. aeruginosa were detected 1 day after wound inocula-
tion and levels decreased to 0 over 2 weeks. In the non-
immunized mice, the colony count increased for 6 days
post-inoculation with P. aeruginosa and the majority of
the mice (80%) died within this period. Table 2 shows the
colony count, survival rate and results of cultures of the
blood, spleen and liver of the non-immunized mice. The
blood cultures of 8%, 32%, 32% and 12% of the non-
immunized mice were positive after 2, 3, 4 and 6 days
post-inoculation, respectively. The spleen and liver cul-
tures were positive in 76% of the mice who died within 6
days of inoculation. Exotoxin A was detected in their sera
2 days post-infection and remained detectable for 6 days.
Table 3 shows the colony count, survival rate, quantity of
exotoxin and anti-exotoxin A and the result of cultures of
Table 1: Antitoxin titer of immunized mice using ELISA
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the blood, spleen and liver of the mice in the experimental
group. As expected, no exotoxin A was detected in the sera
by CIEP, which may be due to neutralization of the toxin
by previously antitoxins formed following immunization.
Bacterial infection is a major complication after thermal
injury, especially in developing countries [16-18]. 75% of
deaths following burns are related to microbial infections
[19]. P. aeruginosa is a frequently isolated bacterium that
causes septicemia and death [17]. It is a ubiquitous oppor-
tunistic, non-fermenting, gram-negative rod that can
infect patients with impaired immune systems. Treatment
of P. aeruginosa infection is frequently hindered by antibi-
otic resistance, and multi-drug resistant strains are mostly
isolated from burn wound infections [3,4,20]. An efficient
vaccine is therefore needed. After colonizing the site of the
burn, P. aeruginosa produces several virulence factors, such
as exotoxin A, alkaline protease and elastase, which affect
the host tissue. High titers of antitoxin against exotoxin A
in patients infected with P. aeruginosa reduces the risk sep-
ticemia and death [9,21].
Conclusion
Exotoxin A is the principal lethal factor of P. aeruginosa. It
seems logical that a toxoid of exotoxin A could be used as
an effective vaccine. Our study shows that in mice immu-
nized with semi-purified exotoxin A, a protective titer of
antitoxin developed that effectively prevented the experi-
mentally infected animals from septicemia and death. The
majority (93.8%) of immunized infected mice survived
during 70 days of observation after a burn wound was
inoculated with P. aeruginosa while all the non-immu-
nized mice in the control group died. The rising antibody
titer in the surviving mice and the decrease in the mortal-
ity rate indicate the presence of an effective antitoxin in
the immunized mice.
Pavlovskis et al. [22] found that the survival rate did not
increase significantly following active immunization with
a toxoid of exotoxin A and infection with P. aeruginosa in
burned mice. However, Matsumato et al. [5] found that
immunization with a combination of alkaline protease
and toxoid of exotoxin A decreased mortality. Some inves-
tigators have reported that active immunization with a
lipopolysaccharide and an outer membrane protein
(OMP) of P. aeruginosa could control the infection in the
burned area [23,24]. Our study, using a semi-purified exo-
toxin A that contained trace amounts of LPS and OMP,
points to a higher efficacy than a toxoid prepared from
purified exotoxin A. Our study did not include different
strains of the bacterium but our results can be used for fur-
ther studies on the purification of, and determination of
cross-immunization of, different strains of the bacterium
[25].
Three of the immunized mice (6.3%) died. This may be
due to the presence of invasive factors other than exotoxin
Table 2: Survival rates, presence of exotoxin A, culture results and colony counts in the control group (non-immunized mice) 
inoculated with P. aeruginosa
Post-inoculation time 
(day)
Number of animals alive 
(survival rate, %)
CFU/mL from inoculated 
burns
Exotoxin A in sera (%)* Positive culture (%)
Liver Spleen Blood
1 25 (100) 1 × 108 -- - -
2 25 (100) 1.14 × 108 2 (8) - - 2 (8)
3 12 (48) 1.25 × 108 8 (32) 2 (8) 2 (8) 8 (32)
4 8 (32) 1.6 × 108 8 (32) 8 (32) 8 (32) 8 (32)
6 5 (20) 1.7 × 108 3 (12) 5 (20) 5 (20) 3 (12)
* detected with CIEP
Table 3: Survival rates, presence of exotoxin A, culture results and colony counts in the experimental group (immunized mice) 
inoculated with P. aeruginosa
Post-inoculation 
time (day)
Number of  
animals alive
(survival rate, %)
CFU/mL from  
inoculated
burns










1 48 (100) 1.5 × 108 ND 48 (100) - - -
4 48 (100) 1.4 × 107 ND 48 (100) - - -
7 47 (98) 1.3 × 106 ND 47 (100) 1 (2) 1 (2) 1 (2)
11 46 (96) 1.2 × 105 ND 47 (98) 1 (2) 1 (2) 1 (2)
14 45 (94) 1 × 104 ND 45 (94) 1 (2) 1 (2) 1 (2)
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A, such as elastase, alkaline protease, hemolysins, leukoci-
din, siderophores, siderophore uptake systems and pyocy-
anin diffusible pigment. Passive immunization was not
evaluated in this study: We chose to study active immuni-
zation because this could play a role in high-risk occupa-
tions such as fire fighting and baking. Our results
demonstrate that in a mouse model of bacterial infection
in burn wounds, active immunization with semipurified
exotoxin A protected against infection with P. aeruginosa
and reduced mortality.
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